Showing 271-280 of 2070 results for "".
Drugs in Development for Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/drugs-in-development-for-multiple-sclerosis/31632/Stem cells, tyrosine kinase inhibitors, remyelinating agents, metabolically active molecules, and more are being tested as potential new disease-modifying treatments.Genetic Mechanisms of Epilepsy
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/genetic-mechanisms-of-epilepsy/31588/Understanding gene and protein functions can sometimes guide diagnosis and treatment.Neuromuscular Notes: Neuromuscular Ultrasound in Polyneuropathy
https://practicalneurology.com/diseases-diagnoses/imaging-testing/neuromuscular-notes-neuromuscular-ultrasound-in-polyneuropathy/31677/A standardized evidence-based and expert approach to ultrasound for diagnosis of polyneuropathy is described.Management of Poststroke Mobility and Spasticity
https://practicalneurology.com/diseases-diagnoses/stroke/management-of-poststroke-mobility-and-spasticity/32187/Mobility and spasticity management tailored appropriately to the individual’s needs and abilities, as well as early rehabilitation, result in reduced disability levels and optimized outcomes after stroke.Treatment of Movement Disorders with Neuromodulation
https://practicalneurology.com/diseases-diagnoses/movement-disorders/treatment-of-movement-disorders-with-neuromodulation/32040/Effective surgical treatments are available for Parkinson disease, essential tremor, and dystonia.Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/bruton-tyrosine-kinase-inhibition-in-multiple-sclerosis/31872/The missing link for treatment optimization?Monitoring Disease Course and Treatment Response in Various Populations With Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/monitoring-disease-course-and-treatment-response-in-various-populations-with-multiple-sclerosis/33144/Monitoring for signs of disease activity or progression in multiple sclerosis—a crucial component of disease management—may need refinement for pediatric, pregnant or postpartum, older, and minority or underserved populations.Early Recognition + Earlier Intervention = Slowing the Progression in Mild Cognitive Impairment / Early Alzheimer’s
https://practicalneurology.com/programs/cme/early-recognition-earlier-intervention-slowing-the-progression-in-mild-cognitive-impairment-early-alzheimers/24279/Tune in to learn about early recognition and the latest on diagnosing and treating patients with mild cognitive impairment and early Alzheimer’s.Incorporating FcRn Inhibitors Into Clinical Practice in Chronic Inflammatory Demyelinating Polyneuropathy
https://practicalneurology.com/programs/cme/incorporating-fcrn-inhibitors-into-clinical-practice-in-chronic-inflammatory-demyelinating-polyneuropathy/27135/Tune in to learn more about how to incorporate FcRn inhibitors into clinical practice for inflammatory demyelinating polyneuropathy (CIDP).Multiple Sclerosis Treatment in Racial and Ethnic Minorities
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/multiple-sclerosis-treatment-in-racial-and-ethnic-minorities/31634/Systematic literature review shows little evidence to guide treatment.